Trifluoperazine 2HCl: Potent Dopamine D2 Receptor Inhibitor for Neuropharmacology Research

Executive Summary: Trifluoperazine 2HCl is a phenothiazine derivative and high-affinity dopamine D2 receptor inhibitor (IC50 = 1.1 nM) with a molecular weight of 480.42 and chemical formula C21H24F3N3S·2HCl [APExBIO]. This compound demonstrates high solubility in DMSO (≥24.02 mg/mL), water (≥48 mg/mL), and ethanol (≥7.26 mg/mL with ultrasonic assistance), and is stable when stored at -20°C. Trifluoperazine 2HCl is widely used to study dopaminergic signaling, modulate macrophage function via autophagy and reactive oxygen species (ROS) induction, and screen candidate therapeutics in cancer models [Epoxomicin.com]. Experimental evidence shows phenothiazines enhance macrophage antibacterial activity through ROS and autophagy, supporting its use in immunology research [Qiu et al., 2025]. Proper handling and freshly prepared solutions are recommended for experimental reproducibility.

Biological Rationale

Trifluoperazine 2HCl is a research-grade dopamine D2 receptor antagonist, classified within the phenothiazine family [APExBIO]. Dopaminergic signaling is central to neuropsychiatric and neurodegenerative disorders, including schizophrenia and Parkinson's disease [3x-Flag-Peptide.com]. Inhibition of D2 receptors modulates neurotransmitter release, affecting neuronal excitability and plasticity. Phenothiazines, including trifluoperazine, also influence immune cell activity, notably macrophages, by inducing autophagy and ROS, mechanisms relevant in host defense against intracellular bacterial pathogens [Qiu et al., 2025]. This dual impact positions trifluoperazine as a valuable tool in both neuropharmacology and immunology workflows. This article extends previous reviews by integrating evidence from both neuronal and immune cell models to clarify the compound's dual-action profile, as discussed in [GTP-Binding-Protein-Fragment-G-Alpha.com].

Mechanism of Action of Trifluoperazine 2HCl

Trifluoperazine 2HCl competitively binds to dopamine D2 receptors, inhibiting receptor activation with an in vitro IC50 of 1.1 nM [APExBIO]. This blockade suppresses dopaminergic signaling, reducing downstream cAMP modulation and altering neuronal firing patterns. In macrophages, phenothiazines trigger autophagic flux and ROS accumulation, enhancing intracellular bacterial clearance [Qiu et al., 2025]. The induction of autophagy involves increased lysosomal activity, while ROS elevation is necessary for the observed antibacterial effects. These distinct but complementary mechanisms make trifluoperazine a dual-purpose research compound.

Evidence & Benchmarks

• Trifluoperazine 2HCl inhibits dopamine D2 receptor activity with an IC50 of 1.1 nM in radioligand binding assays (https://www.apexbt.com/trifluoperazine-2hcl.html).
• It induces autophagy and increases lysosomal activity in macrophages, leading to enhanced antibacterial effects in vitro and in vivo (Qiu et al., 2025, https://doi.org/10.3389/fimmu.2025.1712724).
• ROS accumulation is a prerequisite for the antibacterial activity of phenothiazines; ROS scavengers abrogate this effect in macrophage assays (Qiu et al., 2025, https://doi.org/10.3389/fimmu.2025.1712724).
• Trifluoperazine 2HCl is highly soluble in DMSO (≥24.02 mg/mL), water (≥48 mg/mL), and ethanol (≥7.26 mg/mL with ultrasonic assistance), supporting flexible assay design (https://www.apexbt.com/trifluoperazine-2hcl.html).
• It displays stability when stored at -20°C and is recommended for use in freshly prepared solutions to avoid degradation (https://www.apexbt.com/trifluoperazine-2hcl.html).
• Perphenazine, a related phenothiazine, reduces organ lesions and inflammation in S. Typhimurium infection models, supporting the translational potential of this compound class (Qiu et al., 2025, https://doi.org/10.3389/fimmu.2025.1712724).

For further reading on practical benchmarks, see [Coagulation-Factor-II.com]; this article updates previous protocols by incorporating new evidence for autophagy and ROS induction.

Applications, Limits & Misconceptions

Trifluoperazine 2HCl is validated for use in research on dopaminergic signaling, neurological disorder modeling (e.g., schizophrenia, Parkinson's disease), and neuropharmacology assays. It is effective in studies of macrophage-mediated immunity, supporting host-pathogen and antibacterial research. The compound is also used in cancer model screening, particularly in medulloblastoma and other dopamine receptor-expressing tumor lines.

Common Pitfalls or Misconceptions

• Trifluoperazine 2HCl is for research use only and is not intended for clinical or diagnostic applications.
• Its dopaminergic effects are context-dependent and may not replicate in non-neuronal cell lines lacking D2 expression.
• Long-term storage of solutions (>1 week) at room temperature can lead to compound degradation and inconsistent results.
• The compound does not directly kill bacteria; its antibacterial action is mediated by host cell pathways (autophagy, ROS).
• Phenothiazine-induced ROS may interfere with redox-sensitive assays if not properly controlled.

Workflow Integration & Parameters

Trifluoperazine 2HCl (SKU B1397, APExBIO) supports both in vitro and in vivo research protocols. For in vitro assays, stock solutions are prepared in DMSO (24.02 mg/mL), water (48 mg/mL), or ethanol (7.26 mg/mL, ultrasonic assistance) [APExBIO]. Working concentrations typically range from 10 nM to 10 μM for D2 receptor inhibition and from 0.1 to 10 μM in macrophage functional assays. Solutions should be freshly prepared and stored at -20°C for maximum stability. Compound handling should minimize exposure to light and air to reduce oxidation risk. For optimal reproducibility, vehicle controls and parallel ROS/autophagy inhibitor controls are recommended. The compound's reproducibility and application breadth are discussed further in [GTP-Binding-Protein-Fragment-G-Alpha.com], whereas this article clarifies recommended storage and handling protocols for sensitive applications.

Conclusion & Outlook

Trifluoperazine 2HCl is a potent, versatile dopamine D2 receptor antagonist from the phenothiazine class, enabling precise modulation of dopaminergic signaling and macrophage function in translational research. Its robust solubility, validated pharmacological benchmarks, and dual-utility profile establish it as a benchmark compound for experimental neuroscience, immunology, and oncology. Future research will further elucidate its roles in host-pathogen interactions and tumor immunology. For detailed product specifications and ordering, visit the Trifluoperazine 2HCl product page at APExBIO.